A fully continuous, downstream process represents one of the most interesting novel purification approaches in the biosimilars industry, because it would enhance the production output while reducing the costs of complex biopharmaceuticals. Since it generally involves several chromatographic steps, the selection of appropriate chromatographic columns is of utmost importance. In this study we compared several commercially available ion-exchange-membrane adsorbers (NatriFlo®, Sartobind® and Mustang®) for the removal of deoxyribonucleic acid (DNA), host cell proteins (HCPs) and monoclonal antibody aggregates in flow-through mode. Design of Experiments (DoEs) was employed to determine the optimal pH and conductivity conditions. We demonstrated that all the anion-exchange-membrane adsorbers were capable of removing DNA and HCPs from monoclonal antibody mixtures below the required threshold across a wide range of sample pH and conductivity values, and that the HCPs' normalized outlet concentration increases almost linearly with the loading, being independent of the HCPs' concentration. No significant differences in the profile of the adsorbed HCPs with respect to the membrane adsorbers were observed, based on 2D electrophoresis analysis data, although they exhibited different binding capacities. Cation-exchange-membrane adsorbers were also tested for the removal of aggregates. The Yamamoto model was used to determine the number of binding sites and estimate the conductivity range for efficient removal of aggregates, while maintaining a high monoclonal antibody recovery. However, the obtained range had to be further fine-tuned experimentally, due to displacement phenomena. Differences in the trends of binding-site number with a change in the pH value for the tested cation-exchange adsorbers indicate slightly different adsorption mechanisms. To obtain optimal process performance, adjustments to the pH and the conductivity were required between the anion- and cation-exchange steps.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.chroma.2019.460518 | DOI Listing |
Adv Biotechnol (Singap)
January 2024
Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai, 200030, China.
SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2) Variants of Concern (VOCs), such as the Omicron sub-variants, present significant challenges in pandemic control due to their capacity to escape antibodies and breach vaccine protections. Discovering antibodies that can tolerate mutations in VOCs and understanding their underlying mechanisms is crucial for developing therapeutics for COVID-19 patients, particularly those for whom other therapies may be unsuitable. Here, we report the neutralization of the Omicron variant by FD20, a broadly active human monoclonal antibody.
View Article and Find Full Text PDFInflamm Res
January 2025
Department of Biochemistry, Cancer Biology, Neuroscience, and Pharmacology, School of Medicine, Meharry Medical College, 1005 D.B. Todd Jr. Blvd, Nashville, TN, USA.
Background: The aberrant expression of α defensin 5 (DEFA5) protein in colonic inflammatory bowel diseases (IBDs) underlies the distinct pathogenesis of Crohn's colitis (CC). It can serve as a biomarker for differentiating CC from Ulcerative colitis (UC), particularly in Indeterminate colitis (IC) cases into UC and CC. We evaluated the specificity of commercially available anti-DEFA5 antibodies, emphasizing the need to further validate their appropriateness for a given application and highlighting the necessity for novel antibodies.
View Article and Find Full Text PDFNaunyn Schmiedebergs Arch Pharmacol
January 2025
Institute of Pharmacy, Nirma University, Gujarat, 382481, India.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) discovery has added a new paradigm to our understanding of cholesterol homeostasis and lipid metabolism. Since its discovery, PCSK9 inhibitors have become a widely investigated therapeutic class for lipid management in cardiovascular diseases and hypercholesterolemia. Scientists have explored different approaches for PCSK9 inhibition, such as monoclonal antibodies (mAbs), gene silencing and gene editing techniques, vaccines, mimetic peptides, and small molecules.
View Article and Find Full Text PDFTelemed J E Health
January 2025
University of Texas Health Science Center San Antonio, San Antonio, Texas, USA.
Regional infusion centers (RICs) played an integral role in treating high-risk patients with COVID-19, with mild to moderate symptoms, who did not need acute hospitalization, with monoclonal antibodies. While any medical provider could place a RIC referral, it was recognized that many people face challenges with accessing care. A dedicated medical team was created to provide telemedical evaluation of patients and place appropriate referrals to RICs.
View Article and Find Full Text PDFImmunohorizons
January 2025
Agilex Biolabs, Adelaide, South Australia, Australia.
Enzyme-linked immunosorbent spot analysis is frequently used to investigate immune responsiveness during clinical trials. However, ELISpot classically utilizes peripheral blood mononuclear cell isolates from whole blood, requiring relatively high blood draw volumes and removing both granulocytes and bound drug. Here, we describe a novel protocol whereby CD45 cells are magnetically isolated from human whole blood and co-incubated with serum isolated from the same subject.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!